Edition:
United States

Amicus Therapeutics Inc (FOLD.OQ)

FOLD.OQ on NASDAQ Stock Exchange Global Market

10.37USD
16 Aug 2019
Change (% chg)

$0.38 (+3.80%)
Prev Close
$9.99
Open
$10.10
Day's High
$10.44
Day's Low
$10.09
Volume
626,368
Avg. Vol
848,422
52-wk High
$14.61
52-wk Low
$8.28

Latest Key Developments (Source: Significant Developments)

Amicus Therapeutics Q2 Loss Per Share $0.36
Thursday, 8 Aug 2019 07:00am EDT 

Aug 8 (Reuters) - Amicus Therapeutics Inc ::AMICUS THERAPEUTICS ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS AND CORPORATE UPDATES.Q2 LOSS PER SHARE $0.36.Q2 EARNINGS PER SHARE ESTIMATE $-0.33 -- REFINITIV IBES DATA.SEES FY 2019 REVENUE $160 MILLION TO $180 MILLION.Q2 REVENUE $44.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $41.1 MILLION.REITERATING FY19 REVENUE GUIDANCE OF $160M-$180M.  Full Article

Amicus Therapeutics, Catalent Biologics Enter Strategic Partnership For Gene Therapy Development And Manufacturing
Tuesday, 2 Jul 2019 07:30am EDT 

July 2 (Reuters) - Amicus Therapeutics Inc ::AMICUS THERAPEUTICS AND CATALENT BIOLOGICS ENTER STRATEGIC PARTNERSHIP FOR GENE THERAPY DEVELOPMENT AND MANUFACTURING.AMICUS THERAPEUTICS INC - ENTERED INTO A STRATEGIC MANUFACTURING AGREEMENT WITH PARAGON GENE THERAPY, A UNIT OF CATALENT BIOLOGICS.AMICUS THERAPEUTICS INC - COLLABORATION INCLUDES MULTIPLE ACTIVE PRECLINICAL LYSOSOMAL DISORDER PROGRAMS.  Full Article

Amicus Therapeutics And Brammer Bio Enter Gene Therapy Collaboration
Monday, 1 Jul 2019 07:00am EDT 

July 1 (Reuters) - Amicus Therapeutics Inc ::AMICUS THERAPEUTICS AND BRAMMER BIO, A PART OF THERMO FISHER SCIENTIFIC, ENTER STRATEGIC GENE THERAPY DEVELOPMENT AND MANUFACTURING COLLABORATION.AMICUS THERAPEUTICS INC - ENTERED INTO A STRATEGIC MANUFACTURING COLLABORATION WITH THERMO FISHER SCIENTIFIC.AMICUS THERAPEUTICS - THERMO FISHER, CO TO DEVELOP PLATFORM MANUFACTURING CAPABILITIES TO SUPPORT BROADER PORTFOLIO OF AAV GENE THERAPY PROGRAMS.  Full Article

Amicus Therapeutics Q1 Loss Per Share $0.56
Wednesday, 8 May 2019 07:01am EDT 

May 8 (Reuters) - Amicus Therapeutics Inc ::AMICUS THERAPEUTICS ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS AND CORPORATE UPDATES.Q1 LOSS PER SHARE $0.56.Q1 REVENUE $34 MILLION VERSUS REFINITIV IBES ESTIMATE OF $37.9 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $-0.31 -- REFINITIV IBES DATA.SEES FY 2019 REVENUE $160 MILLION TO $180 MILLION.SAYS EXPECTS HIGHER REVENUE GROWTH IN SECOND AND FOURTH QUARTERS OF 2019.SAYS COMPANY EXPECTS TO END 2019 WITH APPROXIMATELY $300 MILLION IN CASH ON HAND.  Full Article

Amicus Therapeutics Announces Full-Year 2018 Financial Results
Thursday, 28 Feb 2019 07:00am EST 

Feb 28 (Reuters) - Amicus Therapeutics Inc ::AMICUS THERAPEUTICS ANNOUNCES FULL-YEAR 2018 FINANCIAL RESULTS AND 2019 CORPORATE UPDATES.SEES FY 2019 REVENUE $160 MILLION TO $180 MILLION.FY2019 REVENUE VIEW $175.8 MILLION -- REFINITIV IBES DATA.CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES TOTALED $504.2 MILLION AT DECEMBER 31, 2018..EXPECTS TO END 2019 WITH APPROXIMATELY $300 MILLION IN CASH ON HAND.CURRENT CASH POSITION IS ANTICIPATED TO FUND ONGOING OPERATIONS INTO AT LEAST MID- 2021..  Full Article

Bluebird Bio Appoints Chip Baird From Amicus Therapeutics As CFO
Monday, 11 Feb 2019 06:30am EST 

Feb 11 (Reuters) - bluebird bio Inc ::BLUEBIRD BIO APPOINTS CHIP BAIRD AS CHIEF FINANCIAL OFFICER.BLUEBIRD BIO INC - JEFF WALSH TO ASSUME ROLE OF CHIEF STRATEGY OFFICER.BLUEBIRD BIO INC - JASON COLE TO ASSUME ROLE OF CHIEF OPERATING AND LEGAL OFFICER.BLUEBIRD BIO INC - BAIRD JOINS BLUEBIRD FROM AMICUS THERAPEUTICS.  Full Article

Amicus Therapeutics - Entered Privately Negotiated Exchange Agreements With Some Holders Of 3 Percent Convertible Senior Notes Due 2023
Friday, 8 Feb 2019 07:23am EST 

Feb 8 (Reuters) - Amicus Therapeutics Inc ::AMICUS THERAPEUTICS SAYS ENTERED PRIVATELY NEGOTIATED EXCHANGE AGREEMENTS WITH SOME HOLDERS OF 3.00% CONVERTIBLE SENIOR NOTES DUE 2023 - SEC FILING.AMICUS THERAPEUTICS - HOLDERS OF 3.00% CONVERTIBLE SENIOR NOTES DUE 2023 TO EXCHANGE $32.5 MILLION OF NOTES HELD BY THEM FOR CO'S 5.8 MILLION SHARES.AMICUS THERAPEUTICS INC - AFTER EXCHANGE OF NOTES ABOUT $65.5 MILLION OF NOTES WILL REMAIN OUTSTANDING.  Full Article

Amicus Therapeutics Sees FY19 Revenue $160 Mln To $180 Mln
Monday, 7 Jan 2019 07:00am EST 

Jan 7 (Reuters) - Amicus Therapeutics Inc ::AMICUS THERAPEUTICS PROVIDES FULL-YEAR 2019 STRATEGIC OUTLOOK AND FINANCIAL GUIDANCE.SEES FY 2019 REVENUE $160 MILLION TO $180 MILLION.FY2019 REVENUE VIEW $173.2 MILLION -- REFINITIV IBES DATA.2019 GALAFOLD REVENUE EXPECTED TO NEARLY DOUBLE.POMPE PHASE 3 PROPEL STUDY EXPECTED TO COMPLETE ENROLLMENT AND ADDITIONAL PHASE 2 POMPE DATA IN 2019.ADDITIONAL 2-YEAR DATA FROM PHASE 1/2 CLN6 BATTEN DISEASE CLINICAL STUDY ANTICIPATED MID-YEAR 2019.ONGOING PHASE 1/2 CLN3 BATTEN DISEASE STUDY EXPECTED TO COMPLETE ENROLLMENT IN 2019.PRECLINICAL PROOF OF CONCEPT FOR FABRY AND POMPE GENE THERAPY PROGRAMS EXPECTED IN 2019.COMPANY EXPECTS TO END 2019 WITH APPROXIMATELY $300 MILLION IN CASH ON HAND..CURRENT CASH POSITION IS ANTICIPATED TO FUND ONGOING OPERATIONS INTO AT LEAST MID- 2021..  Full Article

Amicus Therapeutics Q3 loss per share $0.84
Monday, 5 Nov 2018 07:00am EST 

Nov 5 (Reuters) - Amicus Therapeutics Inc ::AMICUS THERAPEUTICS ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS AND CORPORATE UPDATES.Q3 LOSS PER SHARE $0.84.Q3 REVENUE $20.6 MILLION VERSUS I/B/E/S VIEW $23.6 MILLION.Q3 EARNINGS PER SHARE VIEW $-0.28 -- THOMSON REUTERS I/B/E/S.REAFFIRMING HIGHER END OF FY18 REVENUE GUIDANCE OF $80M-$90M.BALANCE SHEET STRENGTH SUFFICIENT TO FUND OPERATIONS INTO AT LEAST 2021.REDUCED NET CASH SPEND GUIDANCE FOR 2018.QTRLY REVENUE WAS IMPACTED BY UNEVEN ORDERING PATTERNS OVER SUMMER MONTHS IN EUROPE.CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES TOTALED $564.4 MILLION AT SEPT 30 VERSUS $358.6 MILLION AT DEC 31, 2017.LOWERING ITS FULL-YEAR 2018 NET CASH SPEND TO $190 TO $210 MILLION.  Full Article

Amicus Acquires Gene Therapy Portfolio Of Ten AAV Programs In Neurologic Lysosomal Storage Disorders
Thursday, 20 Sep 2018 06:00am EDT 

Sept 20 (Reuters) - Amicus Therapeutics Inc ::AMICUS THERAPEUTICS ACQUIRES GENE THERAPY PORTFOLIO OF TEN CLINICAL AND PRE-CLINICAL STAGE AAV PROGRAMS IN NEUROLOGIC LYSOSOMAL STORAGE DISORDERS.AMICUS THERAPEUTICS INC - BALANCE SHEET STRENGTHENED WITH $150 MILLION IN NON-DILUTIVE DEBT FINANCING.AMICUS THERAPEUTICS INC - UNDER TERMS OF AGREEMENT, AMICUS WILL PAY $100 MILLION IN AN UPFRONT CASH PAYMENT TO ACQUIRE ALL OF THESE ASSETS.AMICUS THERAPEUTICS INC - CELENEX SHAREHOLDERS ARE ALSO ELIGIBLE FOR UP TO $15 MILLION IN DEVELOPMENT MILESTONES.AMICUS THERAPEUTICS INC - CLOSED A FIVE-YEAR, SENIOR CREDIT FACILITY WITH BIOPHARMA CREDIT.AMICUS THERAPEUTICS - CELENEX SHAREHOLDERS ARE ALSO ELIGIBLE FOR UP TO $262 MILLION IN BLA/MAA SUBMISSION AND APPROVAL MILESTONES ACROSS MULTIPLE PROGRAMS.AMICUS THERAPEUTICS INC - NEW CREDIT FACILITY CONSISTS OF A $150 MILLION NON-DILUTIVE TERM LOAN.AMICUS THERAPEUTICS INC - AMICUS EXPECTS TO PAY NO MORE THAN $75 MILLION OVER NEXT 4 YEARS IN THESE MILESTONES.AMICUS THERAPEUTICS INC - PROCEEDS FROM LOAN FINANCING WILL BE USED TO SUPPORT COST OF ACQUISITION AND SEVERAL YEARS OF RELATED DEVELOPMENT COSTS.AMICUS THERAPEUTICS INC - TRANSACTION WAS APPROVED BY BOARD OF DIRECTORS OF BOTH COMPANIES AND CLOSED IMMEDIATELY.AMICUS THERAPEUTICS INC - CELENEX SHAREHOLDERS MAY ALSO BE ELIGIBLE FOR UP TO $75 MILLION IN TIERED SALES ($500 MILLION/$750 MILLION) MILESTONE PAYMENTS.  Full Article